Metastatic Cervical Carcinoma clinical trials

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Remote hearing test for head and neck cancer patients on cisplatin or radiation

This study tests a remote hearing test to monitor hearing changes in patients with head and neck cancer getting cisplatin chemotherapy and/or radiation. The goal is to catch hearing loss early so treatment can be adjusted.

SBRT radiation for limited cancer growth on immunotherapy

This trial tests whether targeted external-beam radiation (SBRT) can control a small number of progressing kidney cancer spots while you continue immune checkpoint inhibitor immunotherapy. It may help shrink or stop those specific “oligoprogressive” lesions and prolong benefit from your current immunotherapy.

Early drug study for advanced cancers that have limited options

This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.

New drug plus pembrolizumab for advanced cervical cancer

This trial tests a new experimental drug, PRGN-2009, combined with the immunotherapy pembrolizumab (Keytruda) for people with HPV-related cervical cancer that has come back or spread. It is for those who have already tried pembrolizumab and are looking for another option.

Testing a live tumor test for immune therapy response

This trial uses a special test on live tumor samples to see if it can predict how well immune checkpoint inhibitors (a type of immunotherapy) will work for different cancers. It may help doctors choose the best treatment for you.

Lovastatin plus pembrolizumab for advanced head and neck cancer

This trial tests whether adding lovastatin (a cholesterol-lowering drug) to pembrolizumab (an immunotherapy) works better than pembrolizumab alone for head and neck cancer that has come back or spread. It's for people who haven't had immunotherapy before and aren't already on a statin.

Drug combo before bladder or ureter surgery for advanced cancer

This trial tests two drugs, enfortumab vedotin and pembrolizumab, given before surgery to remove the bladder or ureter in people with advanced bladder or upper urinary tract cancer that has spread to lymph nodes or other organs. The goal is to see if this treatment helps shrink the cancer and improves outcomes.

Testing a new drug for advanced cervical cancer after standard treatments

This trial is testing a new drug called SHR-A2102 against standard chemotherapy for people with advanced cervical cancer that has not responded to platinum-based chemotherapy and an immunotherapy (PD-1 or PD-L1 inhibitor). The goal is to see if the new drug works better and what side effects it may cause.

Tumor-pulse device for spinal cancer fluid spread

This trial tests whether Tumor Treating Fields (a non-surgical device that delivers treatment signals to cancer cells through the scalp/skin) can help people whose breast or lung cancer has spread into the fluid around the spine and brain. It focuses on people who have cancer cells found in spinal fluid and can safely use the device most of the day.

Tegavivint for advanced colorectal cancer after other treatments

This early-phase trial tests an experimental drug called tegavivint for people with advanced colorectal cancer who have already tried several standard treatments. It aims to see if the drug can shrink or slow the growth of tumors.

Enasidenib for IDH2-mutated sinonasal and skull base tumors

This trial tests an oral targeted therapy called enasidenib for people with rare head and neck cancers that have an IDH2 gene mutation. The goal is to see if this drug can shrink or slow the growth of these tumors.

Blood tests and swallowing exercise check-ins for head and neck cancer

This study looks at whether giving swallowing exercises and checking in with questionnaires can help people with metastatic (spreading to neck lymph nodes) head and neck cancers do the exercises correctly. It also uses blood tests to better understand adherence and progress over time.

Clofarabine for advanced bladder cancer

This trial tests the drug clofarabine in people with advanced bladder cancer that has spread or cannot be removed by surgery. It is for those who have already tried standard treatments or chose not to have them.

Study of EVOLVE104 for advanced bladder and squamous cell cancers

This trial tests an experimental drug called EVOLVE104 for people with advanced bladder cancer or certain types of squamous cell cancers. It aims to see if the drug is safe and if it can help shrink tumors.

Lower dose pembrolizumab with chemo for advanced cervical cancer

This trial tests a lower dose of pembrolizumab combined with standard chemotherapy as a first treatment for cervical cancer that has spread, come back, or cannot be removed by surgery. The goal is to see if this combination can help shrink tumors and slow the cancer's growth.

Lymph node removal plus standard treatment for cervical cancer

This Phase 3 trial tests whether removing specific lymph nodes in the lower pelvis and around the aorta, along with standard curative treatment, improves outcomes for people with locally advanced cervical cancer. It is mainly aimed at patients whose scans show pelvic lymph nodes involved but not clearly cancer in the para-aortic nodes.

Looking for cancer cells that carry two markers in the blood

This trial is studying a special type of cell that shows up in the blood of people with certain advanced cancers. It aims to find out if these cells can help doctors better understand the cancer and guide treatment.

Abemaciclib before PSMA cancer therapy for advanced prostate cancer

This trial tests whether taking abemaciclib before a PSMA-targeted radioligand can help people with advanced, treatment-resistant prostate cancer. The goal is to improve how well the PSMA therapy works while staying safe.

Radiation plus chemo-immunotherapy for advanced esophageal cancer

This trial tests whether adding radiation to a combination of chemotherapy and immunotherapy can help people with stage IV esophageal cancer that has spread. It is for those who haven't had any prior treatment for their cancer.

PSMA-targeted radioactive therapy for advanced liver cancer

This trial tests a radioactive treatment called 177Lu-PSMA-617 for advanced liver cancer that has not responded to first-line immunotherapy. You need a PSMA-PET scan first to see if your cancer absorbs the treatment.

Immunotherapy plus surgery versus immunotherapy alone for kidney cancer

This study tests whether adding surgery to remove the kidney improves outcomes compared with continuing immunotherapy without surgery. It is for people with metastatic kidney cancer whose disease has not worsened after initial immunotherapy.

Pembrolizumab plus lenvatinib for advanced cervical cancer

This Phase 2 trial studies whether pembrolizumab and lenvatinib can improve outcomes in people with advanced cervical cancer that has grown or stopped responding to earlier treatments. It may help by boosting the immune system and slowing cancer growth.

Combination targeted drug and immunotherapy for recurrent gynecologic cancers

This trial tests a combination of two new drugs—becotatug vedotin (targeted therapy) and zimberelimab (immunotherapy)—in people with recurrent or metastatic cervical, vulvar, or vaginal cancer. The goal is to see if this combination works after standard treatments like platinum chemotherapy and immunotherapy have been tried.